Bidar's Big Leap: Sai Life Sciences' Capacity Grows

Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has completed Phase II of Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar (Unit IV), Karnataka.

With the addition of 91 KL in Q1 FY26, PB-11 now offers a total capacity of 200 KL, making it the largest single reactor volume block at the site. This expansion brings the facility’s total installed reactor capacity to 700 KL.

CEO & Managing Director Krishna Kanumuri stated:
"This expansion is not just about capacity—it’s about reinforcing our commitment to scalability, reliability, and the evolving complexity of our partners’ programs."

PB-11 is a multi-purpose block designed for large-scale commercial manufacturing. The Bidar Unit IV features 12 production blocks, high-potency API capabilities, advanced QC labs, and specialized technologies such as lyophilization, cryogenic, and high-pressure reactions. It holds approvals from USFDA, PMDA (Japan), and CDSCO (India).

Since 2022, Sai Life Sciences has successfully completed over 75 customer audits, reinforcing its global reputation for quality and regulatory compliance.

News by Rahul Yelligetti.